The dorsal anterior cingulate cortex (dACC) is a core structure for the governing of cognitive control, and recent studies have shown that interindividual differences in dACC anatomy are associated with corresponding differences in the ability for cognitive control. However, individuals differ not only in anatomical features of dACC, but also exhibit substantial variability regarding the biochemical characteristics of the dACC. In this study, we combined magnetic resonance spectroscopy ( 1 H-MRS) and functional magnetic resonance imaging (fMRI), finding that interindividual differences of glutamate levels in the dACC during resting-state predict the strength of the blood-oxygen level-dependent (BOLD) response to a task requiring cognitive control. This relationship was observed in the retrosplenial cortex, the orbitofrontal cortex, the inferior parietal lobe, and the basal ganglia. More specifically, individuals with low resting-state glutamate levels in the dACC showed an increased BOLD response when the task demands were high, whereas high-glutamate individuals showed the opposite pattern of an increased BOLD response when the task demands were low. Thus, we show here that individual variability of glutamate levels is directly related to how the brain implements cognitive control.dichotic listening | default-mode network | gamma-aminobutyric acid D espite the steadily increasing knowledge concerning the neuronal underpinnings of cognitive control processes, little is known regarding the underlying biochemistry. Glutamate is particularly interesting in this respect because it is the most important excitatory neurotransmitter in the brain and also acts as a substantial intermediate in cerebral energy metabolism (1). Glutamate functioning is known to be reduced in several psychiatric disorders associated with an impairment in cognitive control (2), and pharmacologically induced reduction of glutamate levels has been found to alter the blood-oxygen level-dependent (BOLD) response to cognitively demanding tasks (3, 4). Here, we investigate the effect of interindividual variations in levels of glutamate on cognitive control mechanisms in healthy subjects. As target region for this investigation, the dorsal anterior cingulate cortex (dACC) was chosen because it represents a core region for handling cognitive conflict (5) and regulating the engagement of cognitive control processes (6), in addition to having strong connections to the frontoparietal and frontostriatal executive and cognitive control networks (7-9). Furthermore, the dACC is rich in glutamatergic innervation (10), rendering it as the prime candidate for the investigation of how individual glutamate levels affect the neuronal implementation of cognitive control.Individual levels of glutamate were determined in a resting state (rsGlu) in 40 healthy adults, using proton magnetic resonance spectroscopy ( 1 H-MRS) from bilateral voxels located in the dACC (Fig. 1A). The auditory cognitive control paradigm for the functional MRI (fMRI) acquisition has been fre...

No abstract

No abstract

No abstract

No abstract

Schizophrenia is characterized by impaired cognitive functioning, and brain regions involved in cognitive control processes show marked glutamatergic abnormalities. However, it is presently unclear whether aberrant neuronal response is directly related to the observed deficits at the metabolite level in schizophrenia. Here, 17 medicated schizophrenia patients and 17 matched healthy participants underwent functional magnetic resonance imaging (fMRI) when performing an auditory cognitive control task, as well as proton magnetic resonance spectroscopy (1H-MRS) in order to assess resting-state glutamate in the anterior cingulate cortex. The combined fMRI–1H-MRS analysis revealed that glutamate differentially predicted cortical blood-oxygen level-dependent (BOLD) response in patients and controls. While we found a positive correlation between glutamate and BOLD response bilaterally in the inferior parietal lobes in the patients, the corresponding correlation was negative in the healthy control participants. Further, glutamate levels predicted task performance in patients, such that lower glutamate levels were related to impaired cognitive control functioning. This was not seen for the healthy controls. These findings suggest that schizophrenia patients have a glutamate-related dysregulation of the brain network supporting cognitive control functioning. This could be targeted in future research on glutamatergic treatment of cognitive symptoms in schizophrenia.

No abstract

Auditory verbal hallucinations (AVHs) are a subjective experience of “hearing voices” in the absence of corresponding physical stimulation in the environment. The most remarkable feature of AVHs is their perceptual quality, that is, the experience is subjectively often as vivid as hearing an actual voice, as opposed to mental imagery or auditory memories. This has lead to propositions that dysregulation of the primary auditory cortex (PAC) is a crucial component of the neural mechanism of AVHs. One possible mechanism by which the PAC could give rise to the experience of hallucinations is aberrant patterns of neuronal activity whereby the PAC is overly sensitive to activation arising from internal processing, while being less responsive to external stimulation. In this paper, we review recent research relevant to the role of the PAC in the generation of AVHs. We present new data from a functional magnetic resonance imaging (fMRI) study, examining the responsivity of the left and right PAC to parametrical modulation of the intensity of auditory verbal stimulation, and corresponding attentional top-down control in non-clinical participants with AVHs, and non-clinical participants with no AVHs. Non-clinical hallucinators showed reduced activation to speech sounds but intact attentional modulation in the right PAC. Additionally, we present data from a group of schizophrenia patients with AVHs, who do not show attentional modulation of left or right PAC. The context-appropriate modulation of the PAC may be a protective factor in non-clinical hallucinations.